Literature DB >> 11953219

Prevalence of hepatitis virus infections in Kosovar refugees.

M Chironna1, C Germinario, P L Lopalco, F Carrozzini, M Quarto.   

Abstract

OBJECTIVES: To assess the prevalence of viral hepatitis infections in a sample of Kosovar refugees having arrived in southern Italy as a result of the 1999 war in the Balkans.
METHODS: The 526 subjects who enrolled on voluntary basis from all age groups were tested for the prevalence of serologic markers for hepatitis virus types A, B, C, D, and E (HAV, HBV, HCV, HDV, HEV).
RESULTS: Among the 526 refugees, the prevalence of total anti-HAV antibodies was 81%. A relevant finding was the presence of total anti-HAV antibodies in 61% of the children up to 10 years of age. The prevalence of anti-HEV antibodies was 2.5% among the subjects. Fifteen subjects (2.9%) were positive for hepatitis B surface antigen (HBsAg), whereas 17.5% tested positive for anti-hepatitis B core antigen (anti-HBc). In children up to 10 years of age, the prevalence of HBsAg and anti-HBc was found to be 0.4% and 6%, respectively. In subjects aged 11 to 20 years, 4.2% tested positive for HBsAg and 20.2% for anti-HBc. In the age group 21 to 30 years, 7.1% of the subjects were found to be HBsAg carriers, whereas 25.9% were found to be positive for anti-HBc. Among the refugees over 30 years of age, the prevalence of HBsAg was 4.2%, whereas anti-HBc was 43.7%. None of the refugees tested positive for anti-HDV. The prevalence of anti-HCV antibodies was 0.7%.
CONCLUSIONS: The results of this seroepidemiologic study indicate a high circulation of HAV in the Kosovar population, whereas the prevalence of HEV antibodies was low and comparable to that of other European countries. The HBV infection seems to be at an intermediate level of endemicity and an immunization policy against HBV infection, through vaccination of all newborns and children before adolescence, may be advisable. Results of this study indicate that the level of endemicity of HCV infection in the Kosovar population is low.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11953219     DOI: 10.1016/s1201-9712(01)90073-6

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

1.  Assessment of HAV and HEV seroprevalence in children living in post-earthquake camps from Düzce, Turkey.

Authors:  Irfan Sencan; Idris Sahin; Demet Kaya; Sukru Oksuz; Mustafa Yildirim
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 2.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

3.  Effects of armed conflict on child health and development: A systematic review.

Authors:  Ayesha Kadir; Sherry Shenoda; Jeffrey Goldhagen
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

4.  Prevalence and associated risk factors for Hepatitis B and C viruses among refugees in Gambella, Ethiopia.

Authors:  Abiyu Ayele; Dessie Abera; Melese Hailu; Muluken Birhanu; Kassu Desta
Journal:  BMC Public Health       Date:  2020-05-19       Impact factor: 3.295

5.  Hepatitis B and C in dialysis units in Kosova.

Authors:  Skender Telaku; Hajrullah Fejza; Ymer Elezi; Teuta Bicaj
Journal:  Virol J       Date:  2009-06-04       Impact factor: 4.099

Review 6.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

Review 7.  The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis.

Authors:  Christina Greenaway; Ann Thu Ma; Lorie A Kloda; Marina Klein; Sonya Cnossen; Guido Schwarzer; Ian Shrier
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.